Everything below concerns NAD+ biosynthesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide mononucleotide | Often abbreviated NMN |
| Chemical formula | C11H15N2O8P | Beta anomer form |
| Molecular mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | Beta-NMN |
| Appearance | White to off-white powder | Typical laboratory grade |
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
== History == The deficiency was the first metabolic myopathy to be recognized when the physician Brian McArdle described the first case in a 30-year-old man who always experienced pain and weakness after exercise. McArdle noticed this patient's cramps were electrically silent and his venous lactate levels failed to increase upon ischemic exercise. (The ischemic exercise consists of the patient squeezing a hand dynamometer at maximal strength for a specific period, usually a minute, with a blood pressure cuff, which is placed on the upper arm and set at 250 mmHg, blocking blood flow to the exercising arm.) Notably, this is the same phenomenon that occurs when muscle is poisoned in vitro by iodoacetate, which inhibits the breakdown of glycogen into glucose and prevents the formation of lactate; as well as produces an electronically silent muscle contracture. Knowing what occurs to muscle poisoned by iodoacetate, helped McArdle speculate that a glycogenolytic block might be occurring when he first described the disease. McArdle accurately concluded that the patient had a disorder of glycogen breakdown that specifically affected skeletal muscle. The associated enzyme deficiency was discovered in 1959 by W. F. H. M. Mommaerts et al.
Two major sources of noise in PET are scatter (a detected pair of photons, at least one of which was deflected from its original path by interaction with matter in the field of view, leading to the pair being assigned to an incorrect LOR) and random events (photons originating from two different annihilation events but incorrectly recorded as a coincidence pair because their arrival at their respective detectors occurred within a coincidence timing window). In practice, considerable pre-processing of the data is required – correction for random coincidences, estimation and subtraction of scattered photons, detector dead-time correction (after the detection of a photon, the detector must "cool down" again) and detector-sensitivity correction (for both inherent detector sensitivity and changes in sensitivity due to angle of incidence). Filtered back projection (FBP) has been frequently used to reconstruct images from the projections. This algorithm has the advantage of being simple while having a low requirement for computing resources. Disadvantages are that shot noise in the raw data is prominent in the reconstructed images, and areas of high tracer uptake tend to form streaks across the image. Also, FBP treats the data deterministically – it does not account for the inherent randomness associated with PET data, thus requiring all the pre-reconstruction corrections described above.
List of lymphatic nodes of the human body American Society of Lymphology Glymphatic system and Meningeal lymphatic vessels - equivalent for the central nervous system Innate lymphoid cells Lymphangiogenesis Lymphangion Mononuclear phagocyte system Waldemar Olszewski – discovered fundamental processes in human tissues connected with function of the lymphatic system Trogocytosis
== Trafficking == The Golden Triangle (Southeast Asia), specifically Shan State, Myanmar, is the world's leading producer of methamphetamine as production has shifted to ya ba and crystalline methamphetamine, including for export to the United States and across East and Southeast Asia and the Pacific. Concerning the accelerating synthetic drug production in the region, the Cantonese Chinese syndicate Sam Gor, also known as The Company, is understood to be the main international crime syndicate responsible for this shift. It is made up of members of five different triads. Sam Gor is primarily involved in drug trafficking, earning at least $8 billion per year. Sam Gor is alleged to control 40% of the Asia-Pacific methamphetamine market, while also trafficking heroin and ketamine. The organization is active in a variety of countries, including Myanmar, Thailand, New Zealand, Australia, Japan, China, and Taiwan. Sam Gor previously produced meth in Southern China and is now believed to manufacture mainly in the Golden Triangle, specifically Shan State, Myanmar, responsible for much of the massive surge of crystal meth in circa 2019. The group is understood to be headed by Tse Chi Lop, a gangster born in Guangzhou, China who also holds a Canadian passport. Liu Zhaohua was another individual involved in the production and trafficking of methamphetamine until his arrest in 2005. It was estimated over 18 tonnes of methamphetamine were produced under his watch.
Sources: en.wikipedia.org
RBR: 04 × 1.62 Gbit/s = 06.48 Gbit/s bandwidth (data rate of 5.184 Gbit/s or 648 MB/s with 8b/10b encoding) HBR: 04 × 2.70 Gbit/s = 10.80 Gbit/s bandwidth (data rate of 8.64 Gbit/s or 1.08 GB/s) HBR2: 4 × 5.40 Gbit/s = 21.60 Gbit/s bandwidth (data rate of 17.28 Gbit/s or 2.16 GB/s) HBR3: 4 × 8.10 Gbit/s = 32.40 Gbit/s bandwidth (data rate of 25.92 Gbit/s or 3.24 GB/s) UHBR 10: 4 × 10.0 Gbit/s = 40.00 Gbit/s bandwidth (data rate of 38.69 Gbit/s or 4.84 GB/s with 128b/132b encoding and FEC) UHBR 13.5: 4 × 13.5 Gbit/s = 54.00 Gbit/s bandwidth (data rate of 52.22 Gbit/s or 6.52 GB/s) UHBR 20: 4 × 20.0 Gbit/s = 80.00 Gbit/s bandwidth (data rate of 77.37 Gbit/s or 9.69 GB/s) The transmission mode used by the DisplayPort main link is negotiated by the source and sink device (the device accepting the signal) when a connection is made, through a process called Link Training. This process determines the maximum possible speed of the connection. If the quality of the DisplayPort cable is insufficient to reliably handle HBR2 speeds for example, the DisplayPort devices will detect this and switch down to a lower mode to maintain a stable connection. The link can be re-negotiated at any time if a loss of synchronization is detected. Audio data is transmitted across the main link during the video blanking intervals (short pauses between each line and frame of video data).
== Meetings == The APS organizes a four-day annual meeting called the Lorne Proteomics Symposium, traditional starting on the first Thursday of February, in Lorne, Victoria. In addition, the APS is active in organizing other symposia both in Australia and in New Zealand.
=== Metabolic and covalent labeling of glycans === Metabolic labeling of glycans can be used as a way to detect glycan structures. A well known strategy involves the use of azide-labeled sugars which can be reacted using the Staudinger ligation. This method has been used for in vitro and in vivo imaging of glycans.
=== Zinc world === Armen Mulkidjanian's zinc world (Zn-world) hypothesis extends Wächtershäuser's pyrite hypothesis. The Zn-world theory proposes that hydrothermal fluids rich in H2S interacting with cold primordial ocean (or Darwin's "warm little pond") water precipitated metal sulfide particles. Oceanic hydrothermal systems have a zonal structure reflected in ancient volcanogenic massive sulfide ore deposits. They reach many kilometers in diameter and date back to the Archean. Most abundant are pyrite (FeS2), chalcopyrite (CuFeS2), and sphalerite (ZnS), with additions of galena (PbS) and alabandite (MnS). ZnS and MnS have a unique ability to store radiation energy, e.g. from ultraviolet light. When replicating molecules were originating, the primordial atmospheric pressure was high enough (>100 bar) to precipitate near the Earth's surface, and ultraviolet irradiation was 10 to 100 times more intense than now; hence the photosynthetic properties mediated by ZnS provided the right energy conditions for the synthesis of informational and metabolic molecules and the selection of photostable nucleobases. The Zn-world theory has been filled out with evidence for the ionic constitution of the interior of the first protocells.
As a result, they were unable to receive the first payments from the Auxílio Reconstrução fund, valued at $5.1 million real. In June, fears of floods began to worry the people of Porto Alegre, causing thousands to abandon their homes. Porto Alegre only was able to have the "pump houses" - buildings that housed the electric tools necessary to drain floods in the city - functioning again by the start of July.
Sources: en.wikipedia.org
=== Biotherapeutic production === In the last few years, Komagataella had been used for the production of over 500 types of biotherapeutics, such as IFNγ. At the beginning, one drawback of this protein expression system is the over-glycosylation with high density of mannose structure, which is a potential cause of immunogenicity. In 2006, a research group managed to create a new strain called YSH597. This strain can express erythropoietin in its normal glycosylation form, by exchanging the enzymes responsible for the fungal type glycosylation, with the mammalian homologs. Thus, the altered glycosylation pattern allowed the protein to be fully functional.
==== Adrenocortical carcinoma and tumors ==== Adrenocortical carcinoma occurs rarely; the average incidence rate is estimated to be 1–2 cases per million annually. The disease involves the formation of cancerous cells within the cortex of one or both of the adrenal glands. Although these tumors are identified in fewer than two percent of patients diagnosed with hyperandrogenism, the possibility must be considered within this population. In one study, more than half of tumor-affected patients had elevated levels of the androgens androstenedione, dehydroepiandrosterone sulfate, and testosterone. The elevation of androgens caused by adrenocortical carcinomas often causes patients to develop Cushing's syndrome, primary aldosteronism, and hyperandrogenism. The molecular basis of the disease has yet to be elucidated.
=== EC 1.13.11 With incorporation of two atoms of oxygen === EC 1.13.11.1: catechol 1,2-dioxygenase EC 1.13.11.2: catechol 2,3-dioxygenase EC 1.13.11.3: protocatechuate 3,4-dioxygenase EC 1.13.11.4: gentisate 1,2-dioxygenase EC 1.13.11.5: homogentisate 1,2-dioxygenase EC 1.13.11.6: 3-hydroxyanthranilate 3,4-dioxygenase EC 1.13.11.7: deleted EC 1.13.11.8: protocatechuate 4,5-dioxygenase EC 1.13.11.9: 2,5-dihydroxypyridine 5,6-dioxygenase EC 1.13.11.10: 7,8-dihydroxykynurenate 8,8a-dioxygenase EC 1.13.11.11: tryptophan 2,3-dioxygenase EC 1.13.11.12: linoleate 13S-lipoxygenas EC 1.13.11.13: The activity is the sum of several enzymatic and spontaneous reactions EC 1.13.11.14: 2,3-dihydroxybenzoate 3,4-dioxygenase EC 1.13.11.15: 3,4-dihydroxyphenylacetate 2,3-dioxygenase EC 1.13.11.16: 3-carboxyethylcatechol 2,3-dioxygenase EC 1.13.11.17: indole 2,3-dioxygenase EC 1.13.11.18: persulfide dioxygenase EC 1.13.11.19: cysteamine dioxygenase EC 1.13.11.20: cysteine dioxygenase EC 1.13.11.21: Now EC 1.14.99.36, β-carotene 15,15′-monooxygenase EC 1.13.11.22: caffeate 3,4-dioxygenase EC 1.13.11.23: 2,3-dihydroxyindole 2,3-dioxygenase EC 1.13.11.24: quercetin 2,3-dioxygenase EC 1.13.11.25: 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 4,5-dioxygenase EC 1.13.11.26: peptide-tryptophan 2,3-dioxygenase EC 1.13.11.27: 4-hydroxyphenylpyruvate dioxygenase EC 1.13.11.28: 2,3-dihydroxybenzoate 2,3-dioxygenase EC 1.13.11.29: stizolobate synthase EC 1.13.11.30: stizolobinate synthase EC 1.13.11.31: arachidonate 12-lipoxygenase EC 1.13.11.32: Now EC 1.13.12.16, nitronate monooxygenase EC 1.13.11.33: arachidonate 15-lipoxygenase EC 1.13.11.34: arachidonate 5-lipoxygenase EC 1.13.11.35: pyrogallol 1,2-oxygenase EC 1.13.11.36: chloridazon-catechol dioxygenase EC 1.13.11.37: hydroxyquinol 1,2-dioxygenase EC 1.13.11.38: 1-hydroxy-2-naphthoate 1,2-dioxygenase EC 1.13.11.39: biphenyl-2,3-diol 1,2-dioxygenase EC 1.13.11.40: arachidonate 8-lipoxygenase EC 1.13.11.41: 2,4′-dihydroxyacetophenone dioxygenase EC 1.13.11.42: identical to EC 1.13.11.11, tryptophan 2,3-dioxygenase EC 1.13.11.43: lignostilbene αβ-dioxygenase EC 1.13.11.44: Activity is covered by EC 1.13.11.60, linoleate 8R-lipoxygenase and EC 5.4.4.6, 9,12-octadecadienoate 8-hydroperoxide 8S-isomerase EC 1.13.11.45: linoleate 11-lipoxygenase EC 1.13.11.46: 4-hydroxymandelate synthase EC 1.13.11.47: 3-hydroxy-4-oxoquinoline 2,4-dioxygenase EC 1.13.11.48: 3-hydroxy-2-methyl-quinolin-4-one 2,4-dioxygenase EC 1.13.11.49: chlorite O2-lyase EC 1.13.11.50: acetylacetone-cleaving enzyme EC 1.13.11.51: 9-cis-epoxycarotenoid dioxygenase EC 1.13.11.52: indoleamine 2,3-dioxygenase EC 1.13.11.53: acireductone dioxygenase (Ni2+-requiring) EC 1.13.11.54: acireductone dioxygenase [iron(II)-requiring] EC 1.13.11.55: sulfur oxygenase/reductase EC 1.13.11.56: 1,2-dihydroxynaphthalene dioxygenase EC 1.13.11.57: gallate dioxygenase EC 1.13.11.58: linoleate 9S-lipoxygenase EC 1.13.11.59: torulene dioxygenase EC 1.13.11.60: inoleate 8R-lipoxygenase EC 1.13.11.61: linolenate 9R-lipoxygenase EC 1.13.11.62: linoleate 10R-lipoxygenase EC 1.13.11.63: β-carotene 15,15′-dioxygenase EC 1.13.11.64: 5-nitrosalicylate dioxygenase EC 1.13.11.65: carotenoid isomerooxygenase EC 1.13.11.66: hydroquinone 1,2-dioxygenase EC 1.13.11.67: 8′-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.11.68: 9-cis-β-carotene 9′,10′-cleaving dioxygenase EC 1.13.11.69: carlactone synthase EC 1.13.11.70: all-trans-10′-apo-β-carotenal 13,14-cleaving dioxygenase EC 1.13.11.71: carotenoid-9′,10′-cleaving dioxygenase EC 1.13.11.72: 2-hydroxyethylphosphonate dioxygenase EC 1.13.11.73: methylphosphonate synthase EC 1.13.11.74: 2-aminophenol 1,6-dioxygenase EC 1.13.11.75: all-trans-8′-apo-β-carotenal 15,15′-oxygenase EC 1.13.11.76: 2-amino-5-chlorophenol 1,6-dioxygenase EC 1.13.11.77: oleate 10S-lipoxygenase EC 1.13.11.78: 2-amino-1-hydroxyethylphosphonate dioxygenase (glycine-forming) EC 1.13.11.79: aerobic 5,6-dimethylbenzimidazole synthase EC 1.13.11.80: (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase EC 1.13.11.81: 7,8-dihydroneopterin oxygenase EC 1.13.11.82: 8′-apo-carotenoid 13,14-cleaving dioxygenase EC 1.13.11.83: 4-hydroxy-3-prenylphenylpyruvate oxygenase EC 1.13.11.84: crocetin dialdehyde synthase EC 1.13.11.85: exo-cleaving rubber dioxygenase EC 1.13.11.86: 5-aminosalicylate 1,2-dioxygenase EC 1.13.11.87: endo-cleaving rubber dioxygenase EC 1.13.11.88: isoeugenol monooxygenase EC 1.13.11.89: (hydroxymethyl)phosphonate dioxygenase EC 1.13.11.90: [1-hydroxy-2-(trimethylamino)ethyl]phosphonate dioxygenase (glycine-betaine-forming) EC 1.13.11.91: 3-mercaptopropionate dioxygenase EC 1.13.11.92: fatty acid α-dioxygenase
== Function == Erection occurs through parasympathetic innervation, which allows engorgement of the corporal bodies; the bulbospongiosus and ischiocavernosus muscles at the root compress the veins and prevent blood draining from the corpora cavernosa. Following ejaculation, sympathetic stimulation constricts the coiled helicine arteries and the two muscles relax, allowing the cavernous spaces to drain and the penis to become flaccid. The strength and inflexibility of the tunica albuginea covering the corpora blocks venous return and is therefore responsible for maintaining rigidity during an erection.
==== Correspondence to effects ==== Co-administration of quinidine, a potent CYP2D6 enzyme inhibitor, with tramadol, a combination which results in markedly reduced levels of desmetramadol, was found not to significantly affect the analgesic effects of tramadol in human volunteers. However, other studies have found that the analgesic effects of tramadol are significantly decreased or even absent in CYP2D6 poor metabolizers. The analgesic effects of tramadol are only partially reversed by naloxone in human volunteers, hence indicating that its opioid action is unlikely the sole factor; tramadol's analgesic effects are also partially reversed by α2-adrenergic receptor antagonists such as yohimbine, the 5-HT3 receptor antagonist ondansetron, and the 5-HT7 receptor antagonists SB-269970 and SB-258719. Pharmacologically, tramadol is similar to tapentadol and methadone in that it not only binds to the MOR, but also inhibits the reuptake of serotonin and norepinephrine due to its action on the noradrenergic and serotonergic systems, such as its "atypical" opioid activity. Tramadol has inhibitory actions on the 5-HT2C receptor. Antagonism of 5-HT2C could be partially responsible for tramadol's reducing effect on depressive and obsessive–compulsive symptoms in patients with pain and co-morbid neurological illnesses. 5-HT2C blockade may also account for its lowering of the seizure threshold, as 5-HT2C knockout mice display significantly increased vulnerability to epileptic seizures, sometimes resulting in spontaneous death.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.
No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.
Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.